histrelin profile

histrelin: gonadotropin releasing hormone agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

histrelin : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	25077993
CHEMBL ID	1201255
CHEBI ID	5739
SCHEMBL ID	17881
SCHEMBL ID	19409305
SCHEMBL ID	19712198
SCHEMBL ID	22288995
MeSH ID	M0093413

Synonym
orf-17070
histrelina [spanish]
vantaas
histreline [french]
rwj 17070
((imbl)-d-his(sub 6),pro(sub 9)-net)lhrh
supprelin
histrelinum [latin]
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-n(sup tau)-benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
orf 17070
histrelin [usan:inn]
brn 4290557
NCGC00181758-01
histrelin
76712-82-8
D02369
histrelin (usan/inn)
CHEMBL1201255
rwj-17070
chebi:5739 ,
orf 17070rwj 17070
histrelinum
histrelina
histreline
hsdb 7657
h50h3s3w74 ,
unii-h50h3s3w74
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-1-benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
l-pyroglutamyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-n(im)-benzyl-histidyl-l-leucyl-l-arginyl-l-proline ethylamide
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-n(tau)-benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
gtpl3884
SCHEMBL17881
DTXSID50227543 ,
histrelin [inn]
histrelin [hsdb]
histrelin [mi]
histrelin [mart.]
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-nt-benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
histrelin [vandf]
histrelin [who-dd]
histrelin [usan]
SCHEMBL19409305
SCHEMBL19712198
AKOS030573448
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-ntau-benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
l-pyroglutamyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-nim-benzyl-histidyl-l-leucyl-l-arginyl-l-proline ethylamide
Q5871149
(des-gly10,d-his(bzl)6,pro-nhet9)-lhrh
SCHEMBL22288995
supprelin lasupprelin la
des-gly10,(d-his(bzl)6)-lh-rh*ethylamide
l-prolinamide, 5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-1-(phenylmethyl)-d-histidyl-l-leucyl-l-arginyl-n-ethyl-
HY-P0056
CS-0015085
ibhpe-lhrh
l02ae05
lhrh, histidyl(imbzl)(6)-n-ethylprolinamide(9)-des-glycinamide(10)-
5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-n(sup tau)- benzyl-d-histidyl-l-leucyl-l-arginyl-n-ethyl-l-prolinamide
imbzl-his(6), pro(9)-net-gnrh
gnrh, his(imbzl)(6)-n-et-pronh2(9)-
6-his(imbzl)-9-n-et-pronh2-10-des-glynh2-lhrh
luteinizing hormone-releasing factor (pig), 6-(1-(phenylmethyl)-d- histidine)-9-(n-ethyl-l-prolinamide)-10-deglycinamide-
histrelin (mart.)
dtxcid00150034
lhrh, his(imbzl)(6)-n-et-pronh2(9)-
histrelinum (latin)

Excerpt	Reference	Relevance
"Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. "	( Histrelin: in advanced prostate cancer. Deeks, ED, 2010)	3.25
"Histrelin is a luteinising hormone-releasing hormone agonist (LHRH)."	( Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. , 2005)	2.49
"The histrelin implant is a new treatment that provides a continuous slow release of the GnRHa histrelin."	( Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. Clarke, W; Eugster, EA; Flood, L; Gray, W; Kletter, GB; Lee, PA; Neely, EK; Reiter, EO; Saenger, P; Shulman, D; Silverman, L; Tierney, D, 2007)	1.13
"Histrelin is a synthetic gonadotrophin-releasing hormone (GnRH) agonist which, when administered over a prolonged period, suppresses the release of gonadotrophins from the anterior pituitary. "	( Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. Barradell, LB; McTavish, D, 1993)	3.17

Excerpt	Reference	Relevance
"The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. "	( Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty. Eckert, GJ; Eugster, EA; Ray, LA, 2023)	1.73

Excerpt	Reference	Relevance
"Treatment with histrelin microcapsules (300 micrograms peptide/kg) prevented any increase in LH secretion in response to a GnRH challenge 3 days later, indicating a direct action of histrelin on the pituitary gland.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat. Demarest, KT; Ericson, E; Gunnet, JW; Hahn, DW; McGuire, JL, 1991)	0.84

Excerpt	Reference	Relevance
" Additionally, the implant was safe and well tolerated."	( Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. Schlegel, PN, 2006)	0.64
" No significant adverse events occurred."	( Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. Clarke, W; Eugster, EA; Flood, L; Gray, W; Kletter, GB; Lee, PA; Neely, EK; Reiter, EO; Saenger, P; Shulman, D; Silverman, L; Tierney, D, 2007)	0.65

Excerpt	Reference	Relevance
" Testosterone suppression was the primary pharmacodynamic endpoint, with treatment success defined as serum testosterone less than 50 ng/dL."	( An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. Dineen, MK; Kuzma, P; Pentikis, HS; Tierney, DS, 2005)	0.57

Excerpt	Relevance	Reference
" Adjustments in dosage or route of administration were sometimes needed."	( A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Anderson, KE; Bardin, CW; Kappas, A; Spitz, IM, 1990)	0.28
" This study was designed to further compare gonadotrophin responses to GnRH agonist stimulation within and between individual patients in a dose-response manner."	( Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women. Chang, RJ; Cheung, AP, 1995)	0.29

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
gonadotropin releasing hormone agonist	Any drug which binds to gonadotropin-releasing hormone receptors and triggers a response.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
oligopeptide	A peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	24 (26.97)	18.7374
1990's	19 (21.35)	18.2507
2000's	14 (15.73)	29.6817
2010's	25 (28.09)	24.3611
2020's	7 (7.87)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (13.98%)	5.53%
Reviews	10 (10.75%)	6.00%
Case Studies	7 (7.53%)	4.05%
Observational	1 (1.08%)	0.25%
Other	62 (66.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	1.97	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
melatonin [no description available]	2.71	3	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
nitrous oxide Nitrous Oxide: Nitrogen oxide (N2O). A colorless, odorless gas that is used as an anesthetic and analgesic. High concentrations cause a narcotic effect and may replace oxygen, causing death by asphyxia. It is also used as a food aerosol in the preparation of whipping cream.. dinitrogen oxide : A nitrogen oxide consisting of linear unsymmetrical molecules with formula N2O. While it is the most used gaseous anaesthetic in the world, its major commercial use, due to its solubility under pressure in vegetable fats combined with its non-toxicity in low concentrations, is as an aerosol spray propellant and aerating agent for canisters of 'whipped' cream.	2.1	1	0	gas molecular entity; nitrogen oxide	analgesic; bacterial metabolite; food packaging gas; food propellant; general anaesthetic; greenhouse gas; inhalation anaesthetic; NMDA receptor antagonist; raising agent; refrigerant; vasodilator agent
porphobilinogen [no description available]	1.97	1	0	aralkylamino compound; dicarboxylic acid; pyrroles	Escherichia coli metabolite; metabolite; mouse metabolite
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.76	3	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
ether Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.	1.96	1	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	3.11	5	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
nilutamide [no description available]	2.21	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
corticosterone [no description available]	1.96	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	1.98	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2.37	2	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	1.96	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
medroxyprogesterone acetate [no description available]	4.05	3	1	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
cyproterone acetate [no description available]	2	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
medroxyprogesterone [no description available]	4.05	3	1	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	1.96	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.37	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	4.15	2	1	benzenes; phenyl acetates
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	2.05	1	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
buserelin Buserelin: A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.	4	4	0	oligopeptide
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.05	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
imidazolidines [no description available]	2.21	1	0	azacycloalkane; imidazolidines; saturated organic heteromonocyclic parent
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	4.59	7	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.96	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	2.21	1	0	organic molecular entity
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.05	1	0
detirelix detirelix: LHRH antagonist	3.79	2	0
lhrh, acetyl-2-(2-naphthyl)-ala(1)-4-f-phe(2)-trp(3)-arg(6)- LHRH, acetyl-2-(2-naphthyl)-Ala(1)-4-F-Phe(2)-Trp(3)-Arg(6)-: gonadorelin antagonist; RN given refers to all D-isomer	1.96	1	0
beta-endorphin beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).	1.96	1	0
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	2.21	1	0	polypeptide
menotropins Menotropins: Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations.	2.37	2	0
lhrh, ac-dehydro-pro(1)-4-f-phe(2)-trp(3,6)- LHRH, Ac-dehydro-Pro(1)-4-F-Phe(2)-Trp(3,6)-: RN given refers to (L-Pro-D-Phe-D-Trp-D-Trp)-isomer; LHRH antagonist	1.96	1	0
trelstar Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	8.31	13	1
nafarelin Nafarelin: A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.. nafarelin : An oligopeptide comprising of 5-oxo-L-proline, L-histidine, L-tryptophan, L-serine, L-tyrosine, 3-(2-naphthyl)-D-alanine, L-leucine, L-arginine and L-prolylglycinamide residues joined sequence by peptide linkages. It is a gonadotropin releasing hormone agonist that is used to treat central precocious puberty in children and endometriosis in women.	3.77	3	0	oligopeptide	anti-estrogen; gonadotropin releasing hormone agonist
deslorelin deslorelin: Ovuplant is tradename for a short-term-release implant containing deslorelin acetate; RN given refers to D-isomer; RN for cpd without isomeric designation not avail 12/90	7.63	6	1	oligopeptide
kiss1 protein, human Kisspeptins: Intercellular signaling peptides that were originally characterized by their ability to suppress NEOPLASM METASTASIS. Kisspeptins have since been found to play an important role in the neuroendocrine regulation of REPRODUCTION.	3.18	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Familial Precocious Puberty [description not available]	0	11.62	34	4
Puberty, Precocious Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.	1	13.62	34	4
Gender Dysphoria A marked difference between the individual’s expressed/experienced gender and the gender others would assign to the individual, and it must continue for at least six months. (from DSM-5)	0	2.91	3	0
Delayed Puberty [description not available]	0	2.17	1	0
Depression, Endogenous [description not available]	0	2.21	1	0
Cancer of Prostate [description not available]	0	10	16	5
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.21	1	0
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	0	2.21	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1	14.43	32	10
Allergic Reaction [description not available]	0	2.1	1	0
Infection [description not available]	0	2.1	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	2.1	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	2.1	1	0
Absence Seizure [description not available]	0	2.13	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	2.13	1	0
Adenocarcinoma, Basal Cell [description not available]	0	4.74	2	1
Esophageal Hernia [description not available]	0	2.05	1	0
Gastroduodenal Ulcer [description not available]	0	2.05	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	4.74	2	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.05	1	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	0	2.05	1	0
Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	0	2.05	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.05	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.05	1	0
Disease Exacerbation [description not available]	0	5.31	2	2
Stunted Growth [description not available]	0	2.02	1	0
Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.	0	2.02	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	4.06	3	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	1.96	1	0
Recrudescence [description not available]	0	1.96	1	0
Porphyria [description not available]	0	2.37	2	0
Acute Disease Disease having a short and relatively severe course.	0	1.96	1	0
Porphyrias A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.	0	2.37	2	0
Polycystic Ovarian Syndrome [description not available]	0	4.06	3	1
Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.	0	4.06	3	1
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	0	4.27	7	0
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	0	4.27	7	0
Hamartoma A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.	0	2.91	1	0
Froehlich's Syndrome [description not available]	0	2.91	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	4.71	2	1
Weight Gain Increase in BODY WEIGHT over existing weight.	0	3.38	1	1
Metastase [description not available]	0	3.39	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	3.39	1	1
Aura [description not available]	0	2.92	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	0	2.92	1	0
Premenstrual Tension A term used to describe the psychological aspects of PREMENSTRUAL SYNDROME, such as the indescribable tension, depression, hostility, and increased seizure activity in women with seizure disorder.	0	3.36	1	1
Premenstrual Syndrome A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.	0	3.36	1	1
Ache [description not available]	0	1.97	1	0
Cancer of Pelvis [description not available]	0	1.97	1	0
Flushing A transient reddening of the face that may be due to fever, certain drugs, exertion, or stress.	0	1.97	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	1.97	1	0
Sterility, Female [description not available]	0	2.37	2	0
Infertility, Female Diminished or absent ability of a female to achieve conception.	0	2.37	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.37	2	0
Cancer of Ovary [description not available]	0	1.97	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	1.97	1	0
Fibroid [description not available]	0	2.37	2	0
Cancer of the Uterus [description not available]	0	2.66	3	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	0	2.37	2	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	0	2.66	3	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	1.96	1	0
Experimental Neoplasms [description not available]	0	1.96	1	0

histrelin

Description

Cross-References

Synonyms (66)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Dosage Studied

Roles (2)

Drug Classes (1)

Research

Studies (89)

Market Indicators

Research Demand Index: 57.79

Study Types